Obermatt
See Similar Stocks →

ProQR Therapeutics

NAQ:PRQR · NL0010872495
BiotechnologySmall

360

19
Profit price64
Owner Earnings Yield1
Dividend Yield1
Price/Sales36
EV / Gross Profit53
Price/Book87
Return on Capital51
Cash Return on Capital22
Return on Equity31
Profit margins66
Accruals35
Owner Earnings Margin49
Sales growth23
Profit growth28
Reinvestment37
Price momentum21
Debt load51
Refinancing8
Debt Payback1
Liquidity19
Analyst ratings81
Expectations trend50
Market mood23
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

ProQR Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryNetherlands
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2012
Employees185
Websiteproqr.com
ISINNL0010872495
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
DiabetesGeneticsCardiovascularNeurologyNeuroscienceGenetic DisorderObesityCentral Nervous SystemBiotechnologyHealth CareTherapeutics

Description

ProQR Therapeutics N.V. (ProQR) operates as a biotechnology company. The company is dedicated to changing lives by developing RNA therapies for severe rare and common diseases. The company focuses on advancing its proprietary Axiomer RNA-editing plat…

Analysis

Middle-of-the-road

ProQR Therapeutics N.V. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
4
2026

All-time high

36

Mar 2026

All-time low

4

Jun 2026

Average rank

20

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
36
—
—
—
Price/Earnings
35
—
—
—
Price/Book
87
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
53
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare ProQR Therapeutics with its peers
Qiagen
GER:QIA
81
CountryNetherlands
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Galapagos
AEX:GLPG
76
CountryBelgium
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Kuros Biosciences
SWX:KURN
80
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zealand Pharma
CPH:ZEAL
78
CountryDenmark
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Prothena Corporation
NSQ:PRTA
39
CountryIreland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Uniqure
NSQ:QURE
20
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →